Sirolimus Study for Healthy Aging in Older Adults
Treatments studied
This study tests a medication called sirolimus to see if it can help older adults stay healthy and independent. The trial is looking for people aged 65 and older who live at home and do not have serious memory problems or major health conditions like kidney or liver disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years old or older.
- You live independently at home, not in a nursing home or assisted living.
- You do not have dementia or memory loss that affects daily activities.
- You are able to take care of your basic needs like bathing, dressing, and eating.
- You are not currently taking medications that may interact with the study drug sirolimus.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether sirolimus can slow or prevent functional decline (more difficulty with daily activities) in older adults. You may be considered if you’re in the right age range and have no major heart, lung, liver, kidney, or recent bleeding/clotting problems.
This early-phase study tests how a medicine called rapalog affects the body in generally healthy middle-aged adults. It may help researchers understand safety and dosing, but it’s not meant to treat an existing disease.
This trial tests two FDA-approved drugs, rapamycin and everolimus, to see if they can improve immune function in healthy older adults. You may join if you are generally healthy, live independently, and are between 65 and 90 years old.
This Phase 2 trial tests sirolimus (a medicine that affects the immune system) to reduce symptoms and disease activity in adults with active systemic lupus erythematosus (SLE). You may be a good fit if your lupus is currently active despite stable standard treatments.
This trial studies whether sirolimus can be used safely and works over time for LAM, a rare lung disease. You may be able to join if you already use (or cannot use) certain lung-targeting medicines called mTOR inhibitors, and if you can do regular clinic visits and breathing tests.
This study tests whether the drug sirolimus (Rapamune) is safe and effective for people with antiphospholipid syndrome (APS), a condition that increases blood clot risk. It may offer a new option for those whose current treatment is stable.
Hear when a new Aging trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.